Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&A Deals, Week Ending August 9, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Blue Wolf Capital Partners LLC RHA Health Services, LLC N/A Kadiant Behavioral Education for Children with Autism N/A Biotechnology Acquirer Target Price Bayer AG BlueRock Therapeutics $240,000,000 Aquinox Pharmaceuticals, Inc. Neoleukin... Read More »
Summer Slowdown in Healthcare Deals Mixes with Global Uncertainty
After a slow first quarter, deal volume picked up again in the second. Pundits predicted a strong end to 2019, but the preliminary results from July’s deal making seem to indicate otherwise. With 126 transactions reported, July 2019’s deal volume sagged 17% compared with June’s and 18% against the same month in 2018. You may recall that 2018 was a hot year for healthcare transactions, ending with a record 1,908. The fact that June 2019 virtually matched that performance shows how strong the healthcare market became in the second quarter, ending with 151 deals. We may see an upward tick in July numbers, of course, as more deals come to light, and may have to rescind our pooh-poohing here.... Read More »
Health Care M&A Deals, Week Ending August 2, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Biotechnology Acquirer Target Price Endo International plc License to Pracinostat in Canada N/A Exelixis, Inc. License to six drug programs $10,000,000 eHealth Acquirer Target Price NEC Corporation OncoImmunity AS N/A EQT and CPPIB Waystar $2,700,000,000 Dedalus France Web100T... Read More »
Q2:19 Healthcare Deal Value, Services vs. Technology
Healthcare deal value in the second quarter totaled $138.7 billion, a slight 7% decrease from the first quarter’s $149.0 billion. Both quarters in 2019 featured a single, mega-billion-dollar deal—the $74 billion Bristol-Myers Squibb/Celgene deal in Q1 and the $87 billion AbbVie/Allergan hook-up in Q2—while the second quarter of 2018 included Takeda’s $81.5 billion deal for Shire plc. The graph below seems to indicate something terribly wrong happened in the second half of 2018, but the spending totals of those two quarters are more typical than the $100-billion-plus quarters that began in Q4:17. Economic uncertainty is still very present in mid-2019 and could grow into a recession at some... Read More »
Q2:19 Healthcare Deal Volume, Services vs. Technology Sectors
With 431 deals announced in the second quarter, acquisition activity was 9% higher than the 394 transactions announced in the previous quarter. Year over year, however, deal volume was 11% lower than the same quarter in 2018, which had 484 deals. The first quarter of 2019 was the slowest of the previous four quarters, at 394 deals. Happily, the second quarter’s activity picked up, as many deal makers predicted it would. Still, talk of recession has grown more insistent, with deal makers predicting an economic slowdown within 12 months to two years. The urgency to complete deals in 2019 has likely fueled some of the activity we’re seeing this year. Deal volume in the health care services... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
